Jump to any asset
850 assets, updated daily
As of September 11, 2026, Zoetis Inc. (ZTS) trades at $72.96. CleaRank Financial AI rates it Hold with a fair value of $94.00, 28.8% above the current price. Wall Street's consensus target is $94.00 across 18 analysts. RSI at 28 is in oversold territory, and the price is below its 50-day average of $75.56.
Zoetis Inc. (ZTS)
Zoetis Inc. NYSE
$72.96
0.1000 (0.14%)
Latest Price
AI Analyst Consensus
59 / 100
Zoetis Inc. (ZTS) is currently trading at $72.96, significantly below its 50-day and 200-day moving averages ($75.56 and $102.14), with its RSI indicating oversold conditions. The company has experienced a recent revenue contraction of -0.2% year-over-year, with forward estimates also projecting negative growth for the current and next quarters. Wall Street sentiment is mixed, with a 'Hold' consensus rating from 18 analysts, a median price target of $94 suggesting a potential 28.8% upside, and a Wall Street score of 68 out of 100. Insider activity shows a net seller position, with total sales of $2.7 million against $886.4 thousand in purchases over 48 transactions, signaling a moderate sell signal. Despite these headwinds, Zoetis operates in the essential Healthcare sector, specifically within Drug Manufacturers - Specialty & Generic, which typically offers defensive characteristics. The company's dividend yield stands at approximately 2.86%. The current price action and insider selling warrant caution, though the oversold technicals and analyst price targets suggest potential for a rebound if the company can navigate its current revenue challenges and demonstrate a return to growth.
ZTS Price Analysis
Market Metrics
Open
$73.50
Day Range
$71.51 to $73.50
Prev Close
$72.86
Volume
220.0K
52-Week Range
$71.00 to $156.49
Market Cap
$30.11B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Trading at a notable discount to sector peers (-54%), which may indicate undervaluation or specific company headwinds.
ZTS Analysis
Company's Health
3/5
12-Month Analyst Target
+28.84% Upside
Median of 18 analysts (12-month)
$94.00
AI Technical Analysis
Zoetis Inc. (ZTS) is currently trading at $72.96, with its Relative Strength Index (RSI) at 28.02, indicating oversold conditions and a potential for a short-term bounce. The stock is trading below its 50-day and 200-day moving averages ($75.56 and $102.14), and also below its 20-day exponential moving average ($75.17), suggesting a bearish short-to-medium term trend. Volume has been significantly below average recently, with the latest volume at 220,050 compared to a 30-day average of 4,314,950, indicating a lack of conviction from traders. Key support levels are not clearly defined by recent price action relative to moving averages, but the oversold RSI suggests that further significant downside may be limited in the immediate term. The MACD is also in negative territory, indicating bearish momentum.
ProTips
- Consider the moderate insider selling signal and negative revenue growth trends when assessing Zoetis Inc.'s (ZTS) current valuation.
- The stock's oversold RSI of 28.02 suggests a potential for a short-term bounce, but this should be viewed cautiously given the prevailing bearish technicals and fundamental headwinds.
- Monitor upcoming earnings reports and management commentary for signs of a turnaround in revenue growth and improved forward guidance.
Key Catalysts
Bearish
Moderate Insider Selling Signal
Insiders have been net sellers of Zoetis Inc. (ZTS) stock, with total sales of $2.7 million against $886.4 thousand in purchases, indicating a moderate sell signal and potential lack of immediate confidence from management.
Source: Insider Trading DataBearish
Negative Revenue Growth Trend
Zoetis Inc. (ZTS) reported a -0.2% year-over-year revenue growth, and forward estimates project continued contraction for the current and next quarters, posing a risk to future earnings and valuation.
Source: Wall Street EstimatesBullish
Oversold Technical Conditions
The stock's RSI is at 28.02, indicating oversold conditions which historically can precede a short-term price rebound for Zoetis Inc. (ZTS).
Source: Technical AnalysisBullish
Attractive P/E Ratio Relative to Sector
Zoetis Inc. (ZTS) trades at a P/E ratio of 11.84, significantly lower than the sector average of 25.5, suggesting potential undervaluation if growth concerns are addressed.
Source: Fundamental AnalysisMarket Outlook
Zoetis Inc. (ZTS) faces a challenging near-term outlook characterized by negative revenue growth and mixed analyst sentiment, despite its oversold technical position. The median analyst price target of $94 suggests a potential 28.8% upside, but this is contingent on the company reversing its current top-line trajectory and demonstrating a return to growth. The current P/E ratio of 11.84 is attractive relative to the sector average, but this valuation may not be justified if revenue contraction persists. Key factors that could alter this outlook include a successful product launch or market expansion that drives revenue growth, or a significant improvement in the broader animal health market. Conversely, continued competitive pressures, regulatory hurdles, or a failure to innovate could exacerbate current challenges and lead to further downside. The moderate insider selling also suggests a lack of strong conviction from management in the immediate future.
Key Statistics
| Market Cap | 30.11B |
|---|---|
| P/E Ratio | 11.84 |
| EPS (TTM) | 6.13 |
| Dividend Yield | 2.86% |
| 52 Week High | 156.49 |
| 52 Week Low | 71.00 |
Zoetis Inc. (ZTS) presents a mixed fundamental picture, trading at a P/E ratio of 11.84, which is considerably lower than the sector average of 25.5, suggesting potential undervaluation on this metric. However, the company's revenue growth has turned negative, reported at -0.2% year-over-year, and forward estimates from Wall Street analysts project continued revenue contraction for the current and next quarters, with current year revenue growth estimated at -2.00%. This indicates significant challenges in top-line expansion. Profitability, as indicated by the EPS of $6.13, appears strong on a trailing twelve-month basis, but the negative revenue growth raises concerns about future earnings sustainability. The company's market capitalization stands at $30.1 billion. While the P/E ratio is low relative to the sector, the negative revenue growth and moderate insider selling signal a need for caution regarding future performance.
Earnings & Growth Analysis
Zoetis Inc. (ZTS) recently reported earnings that showed a slight beat in the latest quarter, with actual EPS of $1.87 exceeding the estimate of $1.85 by 1.08%, though the stock price reacted negatively with a -5.97% drop. The prior quarter saw an EPS miss of -5.56% against an estimate of $1.62, contributing to a -5.13% stock price decline. Prior to that, an EPS beat of 5.71% in February 2026 was met with a positive stock price reaction of 0.8%. However, a significant miss in December 2025 (-400% surprise) resulted in a -0.41% stock price drop. This earnings history indicates inconsistent performance and a recent negative reaction to even slight positive surprises.
Key Risks
Zoetis Inc. (ZTS) faces significant risks including negative revenue growth trends, with current year estimates projecting a -2.00% contraction, and a recent history of inconsistent earnings performance with negative stock reactions. Insider activity indicates a moderate sell signal, with net sellers dominating recent transactions. Also, the stock is trading well below its key moving averages, suggesting a bearish technical trend that could persist if fundamental challenges are not addressed.
Technical Indicators
| RSI (14) | 28.02 |
|---|---|
| MACD | -0.61 |
| SMA 50 | 75.56 |
| SMA 200 | 102.14 |
RSI
Oversold
SMA Cross
Bearish
Price vs SMA
Bearish
MACD
Bearish
Moving averages show a lagging Death Cross (50-day: $75.56, 200-day: $102.14), price is trading below the 50-day SMA, RSI at 28.0 suggests oversold conditions; potential bounce setup.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.26
Weak correlation
Nasdaq 100 (QQQ)
+0.14
Weak correlation
Bitcoin (BTC)
-0.14
Weak correlation
Gold (XAU)
+0.00
Weak correlation
Check Custom Correlation
Calculating correlation...
ZTS Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Entry Strategies (click to switch)
CONSERVATIVE
$72.23
Slight discount to current
Wait for small dip
AGGRESSIVE
$72.96
At current price
Enter now if confident
Risk Management
STOP LOSS
$68.92
MAX LOSS
-4.6%
Volatility-Adjusted Stop Loss
Calculated based on RSI (28.0) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$74.40
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$75.84
+5% (Conservative)
+3.9% (Aggressive)
TARGET 3
$78.01
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for ZTS is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 11, 2026.Growth of $10,000
A $10,000 investment in ZTS in September 2016 would be worth about $14,244 today, compared with about $35,030 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in ZTS today could grow to about $16,668 by 2036 in the base case, with a bull case near $51,354 and a bear case around $5,410. Projections are statistical simulations, not guarantees.
ZTS Stock Price Prediction: 2030
CleaRank's simulation projects a price near $89.50 for ZTS by 2030 in the base case, from $72.96 today (1.2x over 4 years). The downside path ends near $43.93. These are outcomes of a Monte Carlo simulation run on ZTS's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $53.79 | $76.78 | $110 |
| 2028 | $48.85 | $80.81 | $134 |
| 2029 | $45.92 | $85.04 | $158 |
| 2030 | $43.93 | $89.50 | $182 |
| 2031 | $42.51 | $94.19 | $209 |
| 2032 | $41.46 | $99.13 | $237 |
| 2033 | $40.69 | $104 | $267 |
| 2034 | $40.13 | $110 | $300 |
| 2035 | $39.73 | $116 | $336 |
| 2036 | $39.47 | $122 | $375 |
Method: 10,000 simulated price paths using ZTS's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
ZTS Insider Trading Analysis
Bought
$886.4K
3 Transactions
Sold
$2.7M
2 Transactions
Insiders
22
Active Traders
Avg Transaction
$707.6K
Moderate size
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Mar 4, 2020 | ALAIX JUAN RAMON
Director
|
Sell | 263.7K | $37.2M |
| Feb 19, 2021 | ALAIX JUAN RAMON
Director
|
Sell | 133.1K | $21.4M |
| Feb 21, 2020 | ALAIX JUAN RAMON
Director
|
Sell | 120.4K | $17.1M |
| Nov 13, 2020 | ALAIX JUAN RAMON
Director
|
Sell | 91.7K | $15.2M |
| Feb 20, 2020 | ALAIX JUAN RAMON
Director
|
Sell | 83.8K | $12.1M |
| Mar 5, 2020 | DAVID GLENN C
Chief Financial Officer
|
Sell | 43.8K | $6.2M |
| Feb 23, 2022 | DAVID GLENN C
Officer
|
Sell | 32.4K | $6.1M |
| Jul 22, 2021 | LAGANO ROXANNE
Officer
|
Sell | 22.5K | $4.5M |
| Feb 16, 2021 | DAVID GLENN C
Chief Financial Officer
|
Sell | 26.3K | $4.4M |
| Nov 27, 2019 | KNUPP CATHERINE A
Officer
|
Sell | 28.6K | $3.5M |
Page 1 of 1
Frequently Asked Questions
Is Zoetis Inc. stock a buy right now?
Zoetis Inc. (ZTS) is currently rated a 'Hold' by Wall Street analysts with a median price target of $94, suggesting a potential 28.8% upside from its current price of $72.96. However, the stock exhibits oversold technical conditions and negative revenue growth, alongside moderate insider selling, warranting a cautious approach.
What is Zoetis Inc.'s price target for September 2026?
The median analyst price target for Zoetis Inc. (ZTS) is $94, with a range from $80 to $155. This target implies a potential upside of 28.8% from the current price of $72.96.
What are the biggest risks for Zoetis Inc. stock?
Key risks for Zoetis Inc. (ZTS) include negative revenue growth trends, inconsistent earnings performance, and moderate insider selling. The stock is also trading below its key moving averages, indicating a bearish technical trend.
How is Zoetis Inc. performing financially?
Zoetis Inc. (ZTS) reported a -0.2% year-over-year revenue growth, with forward estimates projecting continued contraction. While its P/E ratio is low relative to the sector, the negative top-line growth raises concerns about future profitability.
What is the Wall Street consensus on Zoetis Inc. stock?
The Wall Street consensus for Zoetis Inc. (ZTS) is 'Hold', with 18 analysts covering the stock. The consensus score is 68 out of 100, with 4 'Strong Buy', 5 'Buy', and 9 'Hold' ratings.
Are insiders buying or selling Zoetis Inc. stock?
Insiders at Zoetis Inc. (ZTS) are net sellers, with total sales of $2.7 million compared to $886.4 thousand in purchases in recent filings. This indicates a moderate sell signal from management.
What is the outlook for Zoetis Inc.'s revenue growth?
The outlook for Zoetis Inc.'s (ZTS) revenue growth is currently negative. Wall Street estimates project a -4.00% revenue growth for the current quarter and -7.00% for the next quarter, with current year growth estimated at -2.00%.